Paper20031332
Approach to radiation therapy in hepatocellular carcinoma.
Ma S and 8 others. Cancer Treat Rev, 2010. Cited by 49 papers, by iCite.
Cite this record
ConductScience Library. Approach to radiation therapy in hepatocellular carcinoma. Papers, record 20031332. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20031332
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics9
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Heavy Ion Radiotherapy | Major topic |
| Liver Neoplasms | Major topic |
| Proton Therapy | Major topic |
| Radiotherapy, Conformal | Major topic |
| Humans | |
| Stereotaxic Techniques | |
| Treatment Outcome | |
| Protons |
Source PubMed
Cited by25
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 49 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41120269 | Circular SNX25 encoded radioresistance augmenter facilitates DNA damage repair in hepatocellular carcinoma by targeting BAG6-GET4 interaction. | Cell Death Dis | 2025 | https://conductscience.org/library/papers/41120269 | PubMed |
| 40332552 | Deciphering cGAS-STING signaling: implications for tumor immunity and hepatocellular carcinoma. | Naunyn Schmiedebergs Arch Pharmacol | 2025 | https://conductscience.org/library/papers/40332552 | PubMed |
| 38216672 | TKT-PARP1 axis induces radioresistance by promoting DNA double-strand break repair in hepatocellular carcinoma. | Oncogene | 2024 | https://conductscience.org/library/papers/38216672 | PubMed |
| 38199981 | TRIM22 induces cellular senescence by targeting PHLPP2 in hepatocellular carcinoma. | Cell Death Dis | 2024 | https://conductscience.org/library/papers/38199981 | PubMed |
| 37703362 | Noninvasive morpho-molecular imaging reveals early therapy-induced senescence in human cancer cells. | Sci Adv | 2023 | https://conductscience.org/library/papers/37703362 | PubMed |
| 36495367 | External radiotherapy combined with sorafenib has better efficacy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis. | Clin Exp Med | 2023 | https://conductscience.org/library/papers/36495367 | PubMed |
| 35995846 | SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. | Cell Death Differ | 2023 | https://conductscience.org/library/papers/35995846 | PubMed |
| 32373215 | PEX5, a novel target of microRNA-31-5p, increases radioresistance in hepatocellular carcinoma by activating Wnt/β-catenin signaling and homologous recombination. | Theranostics | 2020 | https://conductscience.org/library/papers/32373215 | PubMed |
| 31781559 | The Therapeutic Potential of Adipose Tissue-Derived Mesenchymal Stem Cells to Enhance Radiotherapy Effects on Hepatocellular Carcinoma. | Front Cell Dev Biol | 2019 | https://conductscience.org/library/papers/31781559 | PubMed |
| 29928336 | Toll-like receptor 4 and its associated proteins as prognostic factors for HCC treated by post-radiotherapy surgery. | Oncol Lett | 2018 | https://conductscience.org/library/papers/29928336 | PubMed |
| 29607307 | Current and Future Treatment of Hepatocellular Carcinoma: An Updated Comprehensive Review. | J Clin Transl Hepatol | 2018 | https://conductscience.org/library/papers/29607307 | PubMed |
| 29581830 | Orthotopic hepatic cancer: radiofrequency hyperthermia-enhanced intratumoral herpes simplex virus-thymidine kinase gene therapy. | Oncotarget | 2018 | https://conductscience.org/library/papers/29581830 | PubMed |
| 28701219 | Excellent local control and tolerance profile after stereotactic body radiotherapy of advanced hepatocellular carcinoma. | Radiat Oncol | 2017 | https://conductscience.org/library/papers/28701219 | PubMed |
| 28267205 | External beam radiotherapy for unresectable hepatocellular carcinoma. | Cochrane Database Syst Rev | 2017 | https://conductscience.org/library/papers/28267205 | PubMed |
| 27994769 | Targeting Hepatocellular Carcinoma: What did we Discover so Far? | Oncol Rev | 2016 | https://conductscience.org/library/papers/27994769 | PubMed |
| 23616629 | CT-pathologic correlation in primary hepatocellular carcinoma: an implication for target delineation. | J Radiat Res | 2013 | https://conductscience.org/library/papers/23616629 | PubMed |
| 23554758 | Sequential transcatheter arterial chemoembolization, three-dimensional conformal radiotherapy, and high-intensity focused ultrasound treatment for unresectable hepatocellular carcinoma patients. | J Biomed Res | 2012 | https://conductscience.org/library/papers/23554758 | PubMed |
| 23497542 | Particle radiotherapy with carbon ion beams. | EPMA J | 2013 | https://conductscience.org/library/papers/23497542 | PubMed |
| 22991573 | Herbal products: benefits, limits, and applications in chronic liver disease. | Evid Based Complement Alternat Med | 2012 | https://conductscience.org/library/papers/22991573 | PubMed |
| 22969885 | Improved radiosensitizing effect of the combination of etanidazole and paclitaxel for hepatocellular carcinoma in vivo. | Exp Ther Med | 2012 | https://conductscience.org/library/papers/22969885 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20031332
GET https://conductscience.org/api/papers/v1/20031332/cited_by?page=2